Susanna M Zuurbier1, Marcel Arnold2, Saskia Middeldorp3, Anne Broeg-Morvay2, Suzanne M Silvis1, Mirjam R Heldner2, Julia Meisterernst2, Banne Nemeth4, Eva R Meulendijks1, Jan Stam1, Suzanne C Cannegieter4, Jonathan M Coutinho5. 1. Department of Neurology, Academic Medical Centre, Amsterdam, the Netherlands. 2. Department of Neurology, Inselspital Hospital University, Bern, Switzerland. 3. Department of Vascular Medicine, Academic Medical Centre, Amsterdam, the Netherlands. 4. Department of Clinical Epidemiology, Leiden University Medical Centre, Leiden, the Netherlands. 5. Department of Neurology, Academic Medical Centre, Amsterdam, the Netherlands5Division of Neuroradiology, Department of Medical Imaging, University Health Network and the University of Toronto, Toronto, Ontario, Canada.
Abstract
IMPORTANCE: Obesity is a risk factor for deep vein thrombosis of the leg and pulmonary embolism. To date, however, whether obesity is associated with adult cerebral venous thrombosis (CVT) has not been assessed. OBJECTIVE: To assess whether obesity is a risk factor for CVT. DESIGN, SETTING, AND PARTICIPANTS: A case-control study was performed in consecutive adult patients with CVT admitted from July 1, 2006 (Amsterdam), and October 1, 2009 (Berne), through December 31, 2014, to the Academic Medical Center in Amsterdam, the Netherlands, or Inselspital University Hospital in Berne, Switzerland. The control group was composed of individuals from the control population of the Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis study, which was a large Dutch case-control study performed from March 1, 1999, to September 31, 2004, and in which risk factors for deep vein thrombosis and pulmonary embolism were assessed. Data analysis was performed from January 2 to July 12, 2015. MAIN OUTCOMES AND MEASURES: Obesity was determined by body mass index (BMI). A BMI of 30 or greater was considered to indicate obesity, and a BMI of 25 to 29.99 was considered to indicate overweight. A multiple imputation procedure was used for missing data. We adjusted for sex, age, history of cancer, ethnicity, smoking status, and oral contraceptive use. Individuals with normal weight (BMI <25) were the reference category. RESULTS: The study included 186 cases and 6134 controls. Cases were younger (median age, 40 vs 48 years), more often female (133 [71.5%] vs 3220 [52.5%]), more often used oral contraceptives (97 [72.9%] vs 758 [23.5%] of women), and more frequently had a history of cancer (17 [9.1%] vs 235 [3.8%]) compared with controls. Obesity (BMI ≥30) was associated with an increased risk of CVT (adjusted odds ratio [OR], 2.63; 95% CI, 1.53-4.54). Stratification by sex revealed a strong association between CVT and obesity in women (adjusted OR, 3.50; 95% CI, 2.00-6.14) but not in men (adjusted OR, 1.16; 95% CI, 0.25-5.30). Further stratification revealed that, in women who used oral contraceptives, overweight and obesity were associated with an increased risk of CVT in a dose-dependent manner (BMI 25.0-29.9: adjusted OR, 11.87; 95% CI, 5.94-23.74; BMI ≥30: adjusted OR, 29.26; 95% CI, 13.47-63.60). No association was found in women who did not use oral contraceptives. CONCLUSIONS AND RELEVANCE: Obesity is a strong risk factor for CVT in women who use oral contraceptives.
IMPORTANCE: Obesity is a risk factor for deep vein thrombosis of the leg and pulmonary embolism. To date, however, whether obesity is associated with adult cerebral venous thrombosis (CVT) has not been assessed. OBJECTIVE: To assess whether obesity is a risk factor for CVT. DESIGN, SETTING, AND PARTICIPANTS: A case-control study was performed in consecutive adult patients with CVT admitted from July 1, 2006 (Amsterdam), and October 1, 2009 (Berne), through December 31, 2014, to the Academic Medical Center in Amsterdam, the Netherlands, or Inselspital University Hospital in Berne, Switzerland. The control group was composed of individuals from the control population of the Multiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis study, which was a large Dutch case-control study performed from March 1, 1999, to September 31, 2004, and in which risk factors for deep vein thrombosis and pulmonary embolism were assessed. Data analysis was performed from January 2 to July 12, 2015. MAIN OUTCOMES AND MEASURES: Obesity was determined by body mass index (BMI). A BMI of 30 or greater was considered to indicate obesity, and a BMI of 25 to 29.99 was considered to indicate overweight. A multiple imputation procedure was used for missing data. We adjusted for sex, age, history of cancer, ethnicity, smoking status, and oral contraceptive use. Individuals with normal weight (BMI <25) were the reference category. RESULTS: The study included 186 cases and 6134 controls. Cases were younger (median age, 40 vs 48 years), more often female (133 [71.5%] vs 3220 [52.5%]), more often used oral contraceptives (97 [72.9%] vs 758 [23.5%] of women), and more frequently had a history of cancer (17 [9.1%] vs 235 [3.8%]) compared with controls. Obesity (BMI ≥30) was associated with an increased risk of CVT (adjusted odds ratio [OR], 2.63; 95% CI, 1.53-4.54). Stratification by sex revealed a strong association between CVT and obesity in women (adjusted OR, 3.50; 95% CI, 2.00-6.14) but not in men (adjusted OR, 1.16; 95% CI, 0.25-5.30). Further stratification revealed that, in women who used oral contraceptives, overweight and obesity were associated with an increased risk of CVT in a dose-dependent manner (BMI 25.0-29.9: adjusted OR, 11.87; 95% CI, 5.94-23.74; BMI ≥30: adjusted OR, 29.26; 95% CI, 13.47-63.60). No association was found in women who did not use oral contraceptives. CONCLUSIONS AND RELEVANCE: Obesity is a strong risk factor for CVT in women who use oral contraceptives.
Authors: Mayte Sánchez van Kammen; Diana Aguiar de Sousa; Sven Poli; Charlotte Cordonnier; Mirjam R Heldner; Anita van de Munckhof; Katarzyna Krzywicka; Thijs van Haaps; Alfonso Ciccone; Saskia Middeldorp; Marcel M Levi; Johanna A Kremer Hovinga; Suzanne Silvis; Sini Hiltunen; Maryam Mansour; Antonio Arauz; Miguel A Barboza; Thalia S Field; Georgios Tsivgoulis; Simon Nagel; Erik Lindgren; Turgut Tatlisumak; Katarina Jood; Jukka Putaala; Jose M Ferro; Marcel Arnold; Jonathan M Coutinho; Aarti R Sharma; Ahmed Elkady; Alberto Negro; Albrecht Günther; Alexander Gutschalk; Silvia Schönenberger; Alina Buture; Sean Murphy; Ana Paiva Nunes; Andreas Tiede; Anemon Puthuppallil Philip; Annerose Mengel; Antonio Medina; Åslög Hellström Vogel; Audrey Tawa; Avinash Aujayeb; Barbara Casolla; Brian Buck; Carla Zanferrari; Carlos Garcia-Esperon; Caroline Vayne; Catherine Legault; Christian Pfrepper; Clement Tracol; Cristina Soriano; Daniel Guisado-Alonso; David Bougon; Domenico S Zimatore; Dominik Michalski; Dylan Blacquiere; Elias Johansson; Elisa Cuadrado-Godia; Emmanuel De Maistre; Emmanuel Carrera; Fabrice Vuillier; Fabrice Bonneville; Fabrizio Giammello; Felix J Bode; Julian Zimmerman; Florindo d'Onofrio; Francesco Grillo; Francois Cotton; François Caparros; Laurent Puy; Frank Maier; Giosue Gulli; Giovanni Frisullo; Gregory Polkinghorne; Guillaume Franchineau; Hakan Cangür; Hans Katzberg; Igor Sibon; Irem Baharoglu; Jaskiran Brar; Jean-François Payen; Jim Burrow; João Fernandes; Judith Schouten; Katharina Althaus; Katia Garambois; Laurent Derex; Lisa Humbertjean; Lucia Lebrato Hernandez; Lukas Kellermair; Mar Morin Martin; Marco Petruzzellis; Maria Cotelli; Marie-Cécile Dubois; Marta Carvalho; Matthias Wittstock; Miguel Miranda; Mona Skjelland; Monica Bandettini di Poggio; Moritz J Scholz; Nicolas Raposo; Robert Kahnis; Nyika Kruyt; Olivier Huet; Pankaj Sharma; Paolo Candelaresi; Peggy Reiner; Ricardo Vieira; Roberto Acampora; Rolf Kern; Ronen Leker; Shelagh Coutts; Simerpreet Bal; Shyam S Sharma; Sophie Susen; Thomas Cox; Thomas Geeraerts; Thomas Gattringer; Thorsten Bartsch; Timothy J Kleinig; Vanessa Dizonno; Yildiz Arslan Journal: JAMA Neurol Date: 2021-11-01 Impact factor: 29.907
Authors: Mohammed AlSheef; Mastourah Alotaibi; Abdul Rehman Z Zaidi; Areej Alshamrani; Aroub Alhamidi; Syed Ziauddin A Zaidi; Noor Alanazi; Sarah Alhathlool; Ohoud Alarfaj; Mohammed AlHazzaa; Ghaydaa Kullab; Amany Alboghdadly; Amani Abu-Shaheen Journal: Saudi Med J Date: 2020-10 Impact factor: 1.484